Jennifer Woyach, MD of The Ohio State University Comprehensive Cancer Center, Columbus, OH talks about selinexor for chronic lymphocytic leukaemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Selinexor is an inhibitor of XPO1, which has been shown to be overactive in a number of cancers, including CLL. Dr Woyach explains that an inhibitor for XPO1 appears to reduce BTK protein expression and downstream B-cell receptor (BCR) signalling. They are interested in combining it with ibrutinib or other BTK inhibitors; there is a trial assessing this combination (NCT02303392).
Selinexor for CLL – mechanism of action and combination with ibrutinib
